claim: no sars-cov-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic
evidence_1: whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross- neutralizing antibodies to the new species in humans is unclear.", "the question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment.", "summary ivig products manufactured from pre-pandemic plasma do not neutralize sars-cov-2 but contain high neutralizing titers for seasonal coronavirus hcov-229e.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "]: dot [@]: at [mhra]: medicines and healthcare products regulatory agency [jcvi]: joint committee for vaccination and immunisation [pmc]: penske media corporation [ covid-19]: coronavirus disease 2019 [covid-19]: coronavirus disease 2019 [v]: view this template [t]: telephone [e]: email []: you need to accept this checkbox.")